Close
Help




JOURNAL

Clinical Medicine Reviews in Vascular Health

Management Strategies for Type 2 Diabetes: Focus on Vildagliptin

Submit a Paper


Clinical Medicine Reviews in Vascular Health 2010:2

Review

Published on 20 Jan 2010

DOI: 10.4137/CMRVH.S3537


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Reviews in Vascular Health

Abstract

The antidiabetic effect of the dipeptidyl peptidase 4 (DPP-4) inhibitors depends on the prolongation of action of the 2 incretin hormones: glucagon like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) by preventing their rapid degradation by the enzyme DPP-4. The use of the DPP-4 inhibitor vildagliptin is associated with mean reduction in glycosylated hemoglobin (HbA1c) levels ranging from 0.5% to 1.0% compared with baseline or placebo. Head-to-head trials show that vildagliptin is less effective than metformin and rosiglitazone, and equally effective to submaximal doses of pioglitazone and glimepiride. The main advantages of vildagliptin are the decreased risk of hypoglycemia, the neutral effect on body weight, the simplicity of use, and reassuring safety profile for up to 2 years. However, its moderate efficacy, the lack of long-term safety and efficacy data, the need for evaluation in patients with renal insufficiency, and relative high cost represent its major limitations. Overall, vildagliptin may be a useful second agent for patients with type 2 diabetes who are not optimally controlled on metformin. This drug can also be used as monotherapy in patients with mild hyperglycemia who cannot tolerate metformin or a sulfonylurea (SU).



Downloads

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)


Sharing


What Your Colleagues Say About Clinical Medicine Reviews in Vascular Health
Publishing in Clinical Medicine Reviews in Vascular Health was a pleasant experience. The process was fast and fair. The staff were very professional and we were well informed of the progress of the manuscript.
Dr Abd A Tahrani MD (Birmingham Heartlands Hospital, University of Birmingham, UK)
More Testimonials

Quick Links


New article and journal news notification services
Email Alerts RSS Feeds
Facebook Google+ Twitter
Pinterest Tumblr YouTube